Ranolazine

DEA Class; Rx

Common Brand Names; Ranexa, Aspruzyo Sprinkle

• Antianginal, Non-nitrates

Hepatic cirrhosis, including Child-Pugh class A (mild), B (moderate), and C (severe)

Strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir)

CYP3A inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, St. John’s wort)

• Dizziness (6.2%)
• Headache (5.5%)
• Constipation (4.5%)
• Nausea (4.4%)
• Cardiac disorders: Bradycardia, palpitations
• Ear and labyrinth disorders: Tinnitus, vertigo
• Eye disorders: Blurred vision
• Gastrointestinal disorders: Abdominal pain, dry mouth, vomiting, dyspepsia
• General disorders and administrative site adverse events: Asthenia, peripheral edema
• Metabolism and nutrition disorders: Anorexia
• Nervous system disorders: Syncope (vasovagal)
• Psychiatric disorders: Confusional state
• Renal and urinary disorders: Hematuria
• Respiratory, thoracic, and mediastinal disorders: Dyspnea
• Skin and subcutaneous tissue disorders: Hyperhidrosis
• Angioedema
• Renal failure
• Eosinophilia
• Chromaturia
• Blood urea increased
• Hypoesthesia
• Paresthesia
• Tremor
• Pulmonary fibrosis
• Thrombocytopenia
• Leukopenia
• Pancytopenia

Data are unavailable on use in pregnant females to inform any drug- associated risks

Data are not available on presence in human milk, effects on breastfed infants, or effects on milk production